- Field Breakdown: 2025 AIG Women’s Open LPGA
- Lottie Woad’s win has everyone talking. It has Lydia Ko ready to ask questions GOLF.com
- How to Watch, Tee Times: Everything You Need to Know for the 2025 AIG Women’s Open Skratch Golf
- AIG Women’s Open Power Rankings: 20 players to watch at Royal Porthcawl Golf Digest Middle East
- Golf Major Bringing Biggest Women’s Sporting Event to Wales Front Office Sports
Author: admin
-
Field Breakdown: 2025 AIG Women’s Open – LPGA
-
ACS Study Finds Firefighters Face Increased Cancer Risk and Mortality, Especially for Skin and Kidney Cancers
According to the International Association of Fire & Rescue Services, there are more than 15 million firefighters protecting the inhabitants of 60 countries around the world. And while hazardous exposures from fires encountered by firefighters vary, potential risks include several known or suspected carcinogens. The results from a new study by the American Cancer Society (ACS) analyzing the link between being a firefighter and cancer risk and mortality show that being a firefighter increased the mortality risk for most cancers, especially for skin and kidney cancers. Increased mortality risk for prostate, colorectal, and lung cancers was also observed after more years working as a firefighter. Continued efforts to protect firefighters and increase access to cancer screenings, and research on how to prevent cancer and intervene early, are a necessity, concluded the study authors. The study by Teras et al is published in the International Journal of Epidemiology.
Study Methodology
The researchers used data from more than 470,000 male firefighters enrolled in the American Cancer Society Cancer Prevention Study-II cohort to assess associations between occupation as a firefighter and cancer mortality. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were used to compare survival time among firefighters to that of other male participants in the study.
Data were obtained from surveys taken by cancer-free individuals with 36 years of mortality follow-up (from 1982 to 2018). Occupations were categorized according to 1980 Census Bureau groups, and cancer deaths according to the International Classification of Disease.
Results
- Being a firefighter is associated with increased risk of mortality from skin and kidney cancers.
- Increased mortality risk for prostate, colorectal, and lung cancers was also observed after more years working as a firefighter.
- Research on the efficacy of novel screening tools in this population and how to prevent cancer and intervene early is needed.
The researchers found that occupation as a firefighter compared with career professionals, defined as those who reported only executive, managerial, or professional specialty occupations, was associated with most cancers, but strongest for skin (HR = 1.72, 95% CI = 1.14–2.60) and kidney (HR = 1.39, 95% CI = 0.92–2.09) cancer mortality. Suggestive increases in prostate and colorectal cancer mortality were observed with more years as a firefighter, and an association with lung cancer was only apparent after 3 decades of follow-up.
Most associations attenuated with control for confounders and changes in referent group to include all nonfirefighter occupations, but associations with skin and kidney cancers persisted.
“These results support additional associations for occupation as a firefighter and cancer mortality beyond those reported in the most recent International Agency for Research on Cancer evaluation,” concluded the study authors.
Understanding the Long-Term Cancer Risks of Firefighting
“Although this isn’t favorable news, this study shines a spotlight on the long-term risks firefighters face beyond the immediate dangers of fighting a fire,” said Lauren R. Teras, PhD, Senior Scientific Director for the American Cancer Society and lead author of this study, in a statement. “Continued efforts to safeguard the health of firefighters by increasing access to cancer screening, early detection, and prevention are paramount. This population plays a crucial role in our communities as first responders and protectors of life and property.”
Disclosure: Conflict of interest disclosures of all study authors may be found at academic.oup.com/ije.
Continue Reading
-
New blood markers predict kidney disease and mortality in diabetes
Kidney complications in diabetes often progress silently, putting patients at risk of life-threatening outcomes long before any symptoms appear. Identifying individuals with diabetes who are at risk of rapid kidney function decline or early death has challenged doctors for decades, with traditional markers like serum creatinine and urinary albumin falling short of accurately predicting these risks.
Fortunately, a new study that was made available online on July 23, 2025, and published in Volume 16, Issue 4 of the Journal of Cachexia, Sarcopenia and Muscle on August 1, 2025, offers a promising solution. A team of researchers led by Associate Professor Tomohito Gohda from the Department of Nephrology, Juntendo University Faculty of Medicine, Japan, found that two simple blood markers-estimated glomerular filtration rate difference (eGFRdiff) and growth differentiation factor-15 (GDF-15) levels-can independently predict kidney disease progression and mortality in people with diabetes. “Currently, eGFR and urinary albumin, which are commonly used in routine clinical practice, are not sufficient to accurately predict kidney outcomes in individuals with diabetes,” says Dr. Gohda. “The development of novel biomarkers that complement these existing markers may allow for the earlier and more convenient identification of patients at high risk for kidney disease progression and mortality.”
The research team analyzed data from 638 Japanese adults living with diabetes mellitus. Participants were observed for a period of more than 5 years, during which 11.8% experienced significant kidney function decline and 6.9% died from various causes. Blood samples were used to calculate eGFRdiff, a measure that reflects differences between cystatin C- and creatinine-based kidney function estimates, and to determine serum levels of GDF-15, a protein increasingly recognized as a marker of inflammation and frailty. The analysis revealed a powerful link: patients with lower eGFRdiff values faced a dramatically higher risk of chronic kidney disease (CKD) progression, while those with elevated GDF-15 levels were at higher risk of increased mortality. Specifically, every 10-unit increase in eGFRdiff reduced the risk of CKD progression by 33%, while higher GDF-15 levels were strongly linked to an increased risk of death by 235%.
“eGFRdiff may contribute to early risk stratification in diabetic kidney disease and assist in developing personalized treatment strategies, potentially leading to improved quality of life for individuals with diabetes and reduced healthcare costs,” explains Dr. Gohda.
Importantly, this research demonstrated that these two markers provide complementary insights. eGFRdiff, which can reflect muscle mass loss and metabolic changes, was more strongly associated with kidney disease progression. On the other hand, GDF-15, a stress-responsive cytokine linked to inflammation, better predicted mortality risk. This distinction suggests that using the two markers together could enhance precision in identifying which patients are most vulnerable to serious complications.
Globally, diabetes is a leading cause of CKD, which can progress to end-stage kidney disease requiring dialysis-a treatment with profound impacts on patients’ lives and high costs for healthcare systems. Early detection of kidney risk using eGFRdiff and GDF-15 could enable clinicians to tailor interventions sooner, slowing or even preventing disease progression and potentially saving lives.
“Our results suggest that frailty and sarcopenia, driven by inflammation and metabolic abnormalities, may contribute to CKD progression and mortality in individuals with diabetes mellitus,” concludes Dr. Gohda. “eGFRdiff assessment may enhance the identification of high-risk individuals.”
By identifying these simple yet powerful markers, this study offers hope for improved personalized and proactive care in diabetes-a critical advancement as diabetes rates and their complications continue to increase worldwide.
Source:
Journal reference:
Gohda, T., et al. (2025). Association of Difference Between eGFR From Cystatin C and Creatinine and Serum GDF‐15 With Adverse Outcomes in Diabetes Mellitus. Journal of Cachexia Sarcopenia and Muscle. doi.org/10.1002/jcsm.70011.
Continue Reading
-
AI Catches One-Third of Interval Breast Cancers Missed at Screening
An AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published today in Radiology.
Interval breast cancers
“Given the lack of long-term data on breast cancer-related mortality measured over 10 or more years following the initiation of DBT screening, the interval cancer rate was often used as a surrogate marker,” explained study author Manisha Bahl, MD, MPH, breast imaging division quality director and co-service chief at Massachusetts General Hospital and associate professor at Harvard Medical School. “Lowering this rate is assumed to reduce breast cancer-related morbidity and mortality.”
In a study of 1,376 cases, Dr. Bahl and her colleagues retrospectively analyzed 224 interval cancers in 224 women who had undergone DBT screening. On those DBT exams, the AI algorithm (Lunit INSIGHT DBT v1.1.0.0) correctly localized 32.6% (73/224) of cancers that were previously undetected.
“My team and I were surprised to find that nearly one-third of interval cancers were detected and correctly localized by the AI algorithm on screening mammograms that had been interpreted as negative by radiologists, highlighting AI’s potential as a valuable second reader,” Dr. Bahl said.
According to the researchers, the Radiology study may represent the first published research to specifically examine AI assistance in detecting interval cancers on screening DBT exams.
“Several studies have explored the use of AI to detect interval cancers on screening two-dimensional digital mammography exams, but to our knowledge no previously published literature has focused on the use of AI to detect interval cancers on DBT,” Dr. Bahl explained.
Improved Lesion-Level Accuracy
To avoid overestimating the sensitivity of the AI algorithm, Dr. Bahl’s team employed a lesion-specific analysis that “credits” the AI algorithm only when it correctly identifies and localizes the exact site of the cancer.
“In contrast, an exam-level analysis gives AI credit for any positive exam, even if its annotation is incorrect or unrelated to the actual cancer site, which may inflate the algorithm’s sensitivity,” Dr. Bahl said. “Focusing on lesion-level accuracy provides a more accurate reflection of the AI algorithm’s clinical performance.”
Continue Reading
-
Researchers Advocate for Separate Roles Between AI and Humans
New Models Clarify Roles
The authors propose a careful, measured approach to role separation—guided by rigorous clinical validation and real-world evidence—as the most pragmatic path forward. Their framework includes three models:
- AI-First Sequential Model—Where effective, AI processes the initial segment of the workflow (e.g., preparing clinical context from electronic health records), followed by the radiologist providing expert interpretation.
- Doctor-First Sequential Model—The radiologist initiates the diagnostic process while AI performs complementary tasks such as report generation and follow-up recommendations to enhance the workflow.
- Case Allocation Model—Cases are triaged based on complexity and clarity, with some managed entirely by AI, others by a radiologist, and the rest through a combination of both.
“Radiologists are stuck in the worst of both worlds—afraid to trust AI fully, but too reliant to ignore it,” Dr. Rajpurkar said. “Clear role separation breaks this cycle.”
The authors envision institutions implementing their framework through repeated interactions rather than strict, sequential processes.
“We’re providing a framework, but the real innovation will come from frontline radiologists adapting it to their specific needs,” Dr. Rajpurkar said. “Institutions will likely discover hybrid approaches we haven’t even imagined yet.”
For example, a trauma center might use the AI-First model to review chest X-rays overnight, then switch to a Doctor-First model when teaching residents. Under the Case Allocation model, an AI screening system may identify and ‘clear’ normal results, escalating only abnormal cases to the radiologist for review.
“The breakthrough moment comes when practices stop asking ‘Which model?’ and start asking ‘Which model when?’” he said. “That’s where the magic happens—adaptive workflows that respond to real-time clinical needs, not rigid theoretical constructs.”
Implementing their vision will require carefully designed pilot programs to test the models in real clinical environments, measuring accuracy, workflow efficiency, radiologist satisfaction and downstream outcomes.
“Results must be shared openly; the field desperately needs honest case studies,” Dr. Rajpurkar said. “Our framework gives radiologists not another promise of AI magic, but a concrete, practical roadmap for integration that acknowledges both the current limitations and the inevitable evolution of AI.”
The researchers also suggest establishing a clinical certification pathway for AI systems, something no single agency is equipped to handle alone.
“The Food & Drug Administration needs to maintain safety oversight, but clinical certification requires understanding real-world workflow integration, which goes beyond traditional regulatory scope,” Dr. Rajpurkar said. “We need new models, perhaps independent certification bodies with input from multiple stakeholders and consortia that bring together clinical expertise, technical knowledge and implementation experience.”
The researchers are awaiting the emergence of general medical AI systems capable of handling routine tasks, preparing cases, and drafting reports, all while learning the patterns of the practice.
“We’re not there yet,” Dr. Rajpurkar said. “But when these systems can competently manage the breadth of tasks a senior medical resident handles, the entire conversation changes. That’s the inflection point we’re watching for.”
For More Information
Access the Radiology editorial, “Beyond Assistance: The Case for Role Separation in AI-Human Radiology Workflows.”
Read previous RSNA News stories about AI in medical imaging:
Continue Reading
-
NASA Wants To Drop Helicopter Drones On Mars To Scout For Manned Landing Sites
In 2021, NASA’s Jet Propulsion Lab successfully launched the first powered flight on another planet with the Ingenuity drone helicopter, co-developed with AeroVironment, Inc. Now, the two are proposing to do it again, with one big change: They want to launch not one, but six new helicopters, and what’s more, they want to launch them as they’re descending from Mars orbit. Why bother with this pesky “ground” you speak of? Much cheaper to lift off when you’re already in the air.
The mission is called Skyfall, which I guess no one told them was also the name of a James Bond movie. The idea is for a capsule to drop down towards the Martian surface, open up before it impacts, and out will fly the six helicopters. Each drone will then fly a different route, using cameras and radar to scan what’s underneath the surface. This will hopefully detect water, ice, or other resources that would make for a good landing site for an eventual manned mission to the red planet.
It’s even possible that this process could “advance the nation’s quest to discover whether Mars was ever habitable.” Could a robot helicopter dropped from space find aliens on another planet? Probably not, but also, please yes.
Read more: Here’s Every Car Company Volkswagen Owns Right Now
The Importance Of Ingenuity
When it first lifted off from Martian soil, Ingenuity only hoped to traverse 980 feet over the span of a few weeks. Instead, the plucky American aviator covered 10.5 miles over three years. It did finally crash in January 2024, during which it suffered rotor damage too severe to ever get it to fly again. While the cause of the crash remains unknown (kind of hard to do an investigation on Mars), Ingenuity soldiers on, dutifully serving as a static weather station now.
I’d say that was a pretty successful mission, all things considered. Clearly NASA agrees, since the Skyfall mission is effectively a major expansion of Ingenuity; the new helicopter drones will be upgraded versions of that design, made by the same public-private partners, JPL and AeroVision respectively.
Exactly how public vs how private may be shifting, however. AeroVision says that it will be taking on some of the work that JPL originally did “commercializing” Mars drones this time around. That sounds in line with the Trump administration’s push to move traditionally government-run operations, like retrieving astronauts, to corporations instead. NASA is also under threat of crippling proposed budget cuts, so it might not even be able to do the work it used to do.
I, for one, think the Martian aliens will welcome their new American corporate overlords. Either way, Skyfall won’t be lifting off of Earth’s soil until at least 2028. If all goes well, air traffic will be getting pretty thick underneath red skies by the end of the decade.
Want more like this? Join the Jalopnik newsletter to get the latest auto news sent straight to your inbox…
Read the original article on Jalopnik.
Continue Reading
-
Govt to offer electric bikes on two-year instalments
ISLAMABAD:Federal government has announced a major initiative to promote electric vehicles by offering 116,000 electric bikes on a two-year instalment plan. This move aims to reduce reliance on petrol and diesel vehicles, encouraging the use of eco-friendly alternatives and supporting sustainable transportation across the country.
Sources indicate that the subsidy and installment scheme for electric bikes is in its final stages of preparation. Prime Minister Shehbaz Sharif is expected to unveil the new electric vehicle (EV) policy on Independence Day.
The scheme is being developed with the collaboration of the State Bank and the Bank Association. It will offer a subsidy of Rs50,000 for each electric bike and rickshaw. The scheme will be available to individuals aged 18 to 65 years.
Read More: E-bike revolution: a road yet to be taken
The price of each electric bike is estimated to be around Rs250,000, with the subsidy reducing the upfront cost. The remaining amount, over Rs200,000, will be payable in installments.
According to sources, 17 companies have successfully obtained licenses to manufacture electric bikes under the scheme. The policy aims to have 30% of vehicles in the country be electric by 2030.
To ensure the success of the EV policy, the government will provide subsidies worth Rs100 billion over the next five years. The breakdown of this subsidy includes Rs9 billion for the current fiscal year, Rs19 billion for 2027, Rs24 billion for 2028, and over Rs26 billion for 2029. For 2030, approximately Rs23 billion will be allocated.
By 2030, the policy targets the production of 2.213 million electric vehicles. The goal for 2040 is to have 90% of vehicles be electric, with the target for a fully zero-emission vehicle fleet set for 2060.
The promotion of electric vehicles is expected to reduce the cost of imported fuel and eliminate environmental pollution caused by traditional vehicles.
Continue Reading
-
Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL
Image Credit: © Bipul Kumar – stock.adobe.com
A supplemental new drug application seeking the approval of the fixed-duration, all-oral combination of venetoclax (Venclexta) plus acalabrutinib (Calquence) for previously untreated patients with chronic lymphocytic leukemia (CLL) has been submitted to the FDA.1
The application is supported by data from the phase 3 AMPLIFY trial (NCT03836261), which showed a statistically significant improvement in progression-free survival (PFS) with the combination vs standard chemoimmunotherapy in this patient population.1
Findings published in the New England Journal of Medicine showed that the median PFS was not reached with either acalabrutinib plus venetoclax or acalabrutinib plus venetoclax and obinutuzumab (Gazyva) vs 47.6 months with chemoimmunotherapy.2 This translated to a 35% reduction in the risk of disease progression or death with acalabrutinib plus venetoclax (HR, 0.65; 95% CI, 0.49-0.87; P = .0004) and 58% reduction in the risk of disease progression or death with acalabrutinib plus venetoclax and obinutuzumab (HR 0.42; 95% CI, 0.30-0.59; P < .0001).1,2
“This FDA submission marks a milestone for CLL treatment with the potential approval for the first oral combination regimen of venetoclax and acalabrutinib for previously untreated patients with chronic blood cancer,” Svetlana Kobina, vice president of global medical affairs and oncology at AbbVie stated in a news release.1 “This new fixed-treatment duration approach could allow patients the opportunity for time off treatment, if approved, and be potentially practice-changing in frontline CLL care.”
Notably, data from AMPLIFY also supported the European approval of fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab for patients with treatment-naive CLL in June 2025.2
AMPLIFY Trial Overview
AMPLIFY was a global, multi-center, open-label trial evaluating venetoclax plus acalabrutinib alone or in combination with obinutuzumab vs chemoimmunotherapy in patients with previously untreated CLL without 17p deletion or TP53 mutation.1 Upon enrollment, patients were randomly assigned 1:1:1 to receive either acalabrutinib-based regimen for 14, 28-day cycles, or standard-of-care chemoimmunotherapy for 6 cycles.
The study’s primary end point was PFS per independent review committee assessment in the acalabrutinib plus venetoclax arm. Secondary end points comprised PFS in the acalabrutinib plus venetoclax and obinutuzumab arm, overall survival (OS), and undetectable measurable residual disease.
Additional Efficacy and Safety Data
Additional efficacy data from AMPLIFY showed that, at a median follow-up of 40.8 months, the estimated 36-month PFS rate was 76.5% with acalabrutinib plus venetoclax, 83.1% with acalabrutinib plus venetoclax and obinutuzumab, and 66.5% with chemoimmunotherapy (HR, 0.65; 95% CI, 0.49-0.87; P = 0.004).3 The estimated 36-month OS rates were 94.1%, 87.7%, and 85.9% for these respective regimens.
The safety and tolerability profile of the combination regimen was also consistent with the known profiles of each individual agent, and no new safety signals were identified.1 The most common any-grade adverse effects (AE) with the acalabrutinib plus venetoclax regimen were neutropenia, hemorrhage, and COVID-19.
Regarding adverse effects (AE) of clinical interest, the most frequently observed grade 3 or higher event was neutropenia; this was reported in 32.3%, 46.1%, and 43.2% in the acalabrutinib plus venetoclax, acalabrutinib plus venetoclax and obinutuzumab, and chemoimmunotherapy groups, respectively.3 The incidence of any-grade tumor lysis syndrome was low, with an incidence of 0.3% in patients treated with acalabrutinib plus venetoclax compared with 3.1% in patients treated with chemoimmunotherapy. 1
References
- AbbVie submits for U.S. FDA approval of combination treatment of Venclexta (venetoclax) and acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL).News release. AbbVie. July 29, 2025. Accessed July 29, 2025. https://news.abbvie.com/2025-07-29-AbbVie-Submits-for-U-S-FDA-Approval-of-Combination-Treatment-of-VENCLEXTA-R-venetoclax-and-Acalabrutinib-for-Previously-Untreated-Patients-with-Chronic-Lymphocytic-Leukemia-CLL
- Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting. News release. AstraZeneca. June 6, 2025. Accessed July 29, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html
- Brown JR, Seymour JF, Jurczak W, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392(8):748-762. doi:10.1056/NEJMoa2409804
Continue Reading
-
400-million-year-old fish exposes big mistake in how we understood evolution
The coelacanth is known as a “living fossil” because its anatomy has changed little in the last 65 million years. Despite being one of the most studied fish in history, it continues to reveal new information that could transform our understanding of vertebrate evolution. This is revealed in a study published in the journal Science Advances by researchers from the University of São Paulo (USP) in Brazil and the Smithsonian Institution in the United States.
Upon re-examining the cranial musculature of the African coelacanth (Latimeria chalumnae), the authors discovered that only 13% of the previously identified evolutionary muscle novelties for the largest vertebrate lineages were accurate. The study also identified nine new evolutionary transformations related to innovations in feeding and respiration in these groups.
“Ultimately, it’s even more similar to cartilaginous fish [sharks, rays, and chimaeras] and tetrapods [birds, mammals, amphibians, and reptiles] than previously thought. And even more distinct from ray-finned fish, which make up about half of living vertebrates,” says Aléssio Datovo, a professor at the Museum of Zoology (MZ) at USP supported by FAPESP, who led the study.
Among the evolutionary novelties erroneously identified as present in coelacanths are muscles responsible for actively expanding the buccopharyngeal cavity, which extends from the mouth to the pharynx. This set of muscles is directly related to food capture and respiration. However, the study showed that these supposed muscles in coelacanths were actually ligaments, which are structures incapable of contraction.
Ray-finned fish (actinopterygii) and lobe-finned fish (sarcopterygii) diverged from a common ancestor approximately 420 million years ago. The sarcopterygii include fish such as coelacanths and lungfish, as well as all other tetrapods, because they evolved from an aquatic ancestor. These include mammals, birds, reptiles, and amphibians.
In ray-finned fish, such as aquarium carp, it is easy to see how the mouth moves to suck in food. This ability gave actinopterygii a significant evolutionary advantage; today, they comprise about half of all living vertebrates.
This is a fundamental difference from other fish, such as coelacanths and sharks, which primarily feed by biting their prey.
“In previous studies, it was assumed that this set of muscles that would give greater suction capacity was also present in coelacanths and, therefore, would have evolved in the common ancestor of bony vertebrates, which we now show isn’t true. This only appeared at least 30 million years later, in the common ancestor of living ray-finned fish,” points out Datovo.
Behind the scenes
Coelacanths are extremely rare fish that live about 300 meters below the surface of the water and spend their days in underwater caves.
One reason they have changed so little since the extinction of the dinosaurs is that they have few predators and live in a relatively protected environment. This has resulted in slow changes to their genome, as shown by a 2013 study published in the journal Nature.
Coelacanths were first known only from fossils from about 400 million years ago. It was not until 1938 that a living animal was discovered, much to the astonishment of scientists. In 1999, another species (Latimeria chalumnae) was discovered in Asian waters.
Due to the rarity of specimens in museums, researchers from USP and the Smithsonian Institution’s National Museum of Natural History had to persevere to find an institution willing to lend animals for dissection.
The Field Museum in Chicago and the Virginia Institute of Marine Science, both in the United States, finally agreed to lend one specimen each. According to Datovo, G. David Johnson, co-author of the article, deserves credit for obtaining the loan.
Johnson, born in 1945, was “probably the greatest fish anatomist of his time,” according to Datovo. He died in November 2024 after a domestic accident while the study was under review.
Contribution
“Contrary to what it may seem, dissecting a specimen does not mean destroying it as long as it’s done properly,” says Datovo.
The researcher, who has been conducting this type of study for over 20 years, spent six months separating all the muscles and skull bones of the coelacanth. These structures are now preserved and can be studied individually by other scientists, eliminating the need to dissect a new animal.
Seeing each muscle and nerve firsthand allowed the authors to identify what was actually in the coelacanth’s head with certainty, point out previously undescribed structures, and correct errors that had been repeated in the scientific literature for over 70 years.
“There were many contradictions in the literature. When we finally got to examine the specimens, we detected more errors than we’d imagined. For example, 11 structures described as muscles were actually ligaments or other types of connective tissue. This has a drastic consequence for the functioning of the mouth and breathing, because muscles perform movement, while ligaments only transmit it,” he explains.
Due to the position of coelacanths in the vertebrate tree of life, the discovery impacts our understanding of cranial evolution in all other large vertebrate groups.
With this information, the researcher used three-dimensional microtomography images of the skulls of other groups of fish, both extinct and living. These images are made available by other researchers who study fish anatomy when they perform 3D scans.
From images of the skull bones of other fish from completely extinct lineages, Datovo and Johnson were able to infer where the muscles found in coelacanths would fit, elucidating the evolution of these muscles in the first jawed vertebrates. In future work, Datovo intends to analyze similarities with the muscles of tetrapods, such as amphibians and reptiles.
Continue Reading
-
Laura Dahlmeier involved in serious mountaineering accident in Pakistan
Two-time Olympic biathlon gold medallist Laura Dahlmeier of Germany has been involved in a severe mountaineering accident, according to a statement to German broadcaster ZDF from her management team.
“Laura Dahlmeier was climbing with her mountaineering partner on 28 July when she was caught in a rockfall. The accident took place around noon local time at an altitude of approximately 5,700 metres,” the statement said. “Her partner immediately called emergency services, and a rescue operation began immediately. Due to the remoteness of the area, a helicopter was only able to reach the site of the accident on the morning of 29 July.”
The incident took place in Pakistan’s Karakorum mountains, and an international rescue operation is currently underway.
Dahlmeier won two Olympic biathlon gold medals at the Olympic Winter Games PyeongChang 2018, as she claimed the top spot in both the 7.5km sprint and 10km pursuit. She added bronze in the 15km individual event.
At the World Championships, the 31-year-old owns 15 medals, including seven gold.
Dahlmeier announced her retirement from competition in May 2019, at the age of 25.
Continue Reading